Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2

STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to screen for multiple cancers simultaneously (ACS, 2024). Currently, numerous clinical trials are investigating the sensitivity and specificity of MCED tests, their performance in different populations, their impact on patients, and their implementation into the clinical setting (Lennon et al, 2020; Rubinstein et al, 2024; Gao et al, 2023; Schrag et al, 2022; Lennon et al, 2023; Nicholson et al, 2023). In Module 2 of this activity, Dr. Charles Vega, Clinical Professor of Family Medicine in the School of Medicine at the University of California, Irvine, will discuss the latest clinical trial data of MCED tests in gynecologic, gastrointestinal, and hematologic cancers and the insights into the future of MCED that these trials aim to provide.

TARGET AUDIENCE
Oncologists, gastroenterologists, obstetrician-gynecologists, hematologists, advanced practice providers, and other healthcare providers involved in cancer screening

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to

Differentiate MCED tests from other blood-based screening tests
Explain how MCED testing complements existing screening and diagnostic methods in gastrointestinal, gynecologic, and hematologic cancers
Assess current and emerging data supporting the use of MCED tests in clinical practice
Discuss tactics to promote the widespread adoption of cancer screening in the community
Apply practical tools and strategies for integrating the latest cancer screening technologies into the clinical workflow